ZTS: Ascending Triangle detected on 2 Sep 2026

Zoetis forms an ascending triangle pattern with structure score 14.0, volume score 11.0, and breakout score 12.0, combining for overall quality score of 79.0. Current price of $77.25 sits between key support at $75.34 and resistance at $79.20, near the upper half of the formation. Volume ratio of 0.62 signals below-average participation during pattern construction. The 61.61% win probability suggests moderate historical reliability. RSI at 53.18 indicates neutral momentum—neither overbought nor oversold—providing clean technical footing for a potential move higher if resistance breaks decisively.

Zoetis reported Q2 2026 revenue of $2.5 billion (flat versus Q2 2025) and lowered full-year 2026 guidance amid softer companion-animal demand and increased competition. Full-year revenue guidance was cut from $9.68–$9.96 billion to $9.12–$9.32 billion, with organic operational revenue now expected to decline 1%–3% instead of growing 2%–5%. Leadership was restructured with James Saccaro appointed CFO and COO effective August 17, 2026, consolidating global finance and manufacturing oversight. TD Cowen cut its price target to $94 from $104, though maintaining a Buy rating. The livestock segment delivered 12% organic operational growth in Q1 2026, offsetting companion animal revenue decline of 4%. The pattern forms during a critical reset period following guidance cuts—potential stabilization after steep selloff.

An ascending triangle breakout above $79.20 resistance would target the conservative measured move of $80.36—approximately 1.5% above breakout point. Volume confirmation remains critical given the current 0.62 volume ratio; a decisive break should occur on expanding participation near or above 6.5 million shares to validate follow-through. The pattern invalidates decisively below key support at $75.34, representing a 2.5% downside risk from current levels. Historical win probability of 61.61% indicates breakout success occurs roughly two-thirds of the time for similar setups. If this pattern holds and extends, subsequent price action hinges on volume and whether institutional sentiment shifts with new manufacturing leadership and potential operational improvements.

Q2 2026 companion-animal revenue declined 1% organically, reflecting sustained pressure in the U.S. companion-animal market. Analyst price targets have been reduced including TD Cowen lowering from $104 to $94 amid dermatology franchise weakness and competitive pressure. Consensus analyst rating stands at Hold with major firms including Barclays and Stifel slashing price targets. The stock trades 49.33% below its 52-week high of $156.49, signaling broader momentum loss. Beta of 0.82 provides some downside protection, but the health care sector regime is neutral (bearish broader market at -0.23). No immediate earnings catalyst before late October likely. Short interest has fallen 21%, suggesting some short covering but not sufficient fundamental conviction to drive sustained rallies.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.